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Abstract
Stromal fibroblasts, the most abundant and probably the most active cellular component of breast cancer–associated
stroma, become active and promote angiogenesis through paracrine effects. However, it still unclear how these pro-
cesses are regulated. Here, we have shown that down-regulation of the tumor suppressor p16INK4A protein enhances
the migration/invasion abilities of breast stromal fibroblasts, which form dendritic network of extensions into matrigel.
Furthermore, we present clear evidence that p16INK4A represses the expression/secretion of the proangiogenesis pro-
tein vascular endothelial growth factor A (VEGF-A). Consequently, p16INK4A-deficient breast stromal fibroblasts and
mouse embryonic fibroblasts enhanced endothelial cell differentiation into capillary-like structures in a paracrine man-
ner. This effect was suppressed by adding bevacizumab, a specific VEGF-A inhibitor. Additionally, p16INK4A-defective
mouse embryonic fibroblasts enhanced angiogenesis in breast cancer xenografts in mice. Furthermore, we have
shown that p16INK4A suppresses the Akt/mammalian target of rapamycin (mTOR) signaling pathway and its down-
stream effector hypoxia-inducible factor 1-alpha (HIF-1α), which transactivates VEGF-A. Consequently, Akt inactivation
suppressed both the p16INK4A-dependent autocrine effect on fibroblast migration/invasion and the paracrine effect on
angiogenesis, showing the important role of this protein kinase in mediating the various effects related to p16INK4A
deficiency. These results indicate that p16INK4A is an efficient inhibitor of the migration/invasion abilities of breast
stromal fibroblasts and also their paracrine proangiogenic effects, through inhibition of Akt. Therefore, pharmacologic
restoration of p16INK4A level in stromal fibroblasts may be exploited as therapeutic strategy to help eradicate tumor
cells and/or prevent their recurrence, through suppressing cell non-autonomous procarcinogenic mediators.
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Introduction
Cancer-associated fibroblasts, which constitute the major component
of tumor stroma, play crucial roles in tumor onset and progression
[1–3]. It has been shown that stromal fibroblasts present in invasive
human breast carcinomas promote tumor growth through elevated
SDF1 secretion and stimulation of tumor angiogenesis [4]. This pro-
cess enables the growth of new blood vessels from adjacent micro-
vessels, which provide nutrition and oxygen to the growing tumor
allowing its growth and expansion. One key mediator of this impor-
tant cancer-promoting process is the vascular endothelial growth fac-
tor A (VEGF-A) [5,6]. In a recent study, it has been shown that
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VEGF-A secreted by reactive mouse mammary gland stromal cells
enhances angiogenesis in xenografted human breast tumors [7]. Inter-
estingly, the VEGF-A cytosolic levels in tumor tissue samples have
been shown to be indicative of prognosis for patients with node-
negative breast carcinoma [8]. It is noteworthy that this gene is tightly
regulated at both transcriptional and post-transcriptional levels and
that the Akt pathway plays a major role in this regulation [9–12].
p16INK4A (hereafter referred to as p16) is a cyclin-dependent kinase
(CDK) inhibitor that plays multiple biologic functions, including the
inhibition of cell cycle progression [13], the modulation of DNA
damage–induced apoptosis [14], and the induction of senescence
[15,16]. CDKN2A is an important tumor suppressor gene, which is
frequently inactivated by point mutations, promoter methylation, or
deletion in virtually all types of human cancers, including breast
carcinomas [17–19]. Notably, p16-related tumor suppressor functions
have been extensively studied in tumor cells, paying only little attention
to its potential cell non-autonomous effects from the surrounding stromal
cells, including fibroblasts. Importantly, we have recently shown that p16
is downregulated in most breast cancer–associated fibroblasts and has
also cell non-autonomous tumor suppressor function [20].
In the present report, we present clear evidence that p16 down-
regulation enhances the migration/invasion of stromal fibroblasts
and their paracrine VEGF-A–dependent angiogenesis through activa-
tion of the Akt protein kinase.
Materials and Methods
Cells, Cell Culture, and Chemicals
Breast cancer associated fibroblast 64 (CAF-64) and tumor counter-
part fibroblast 64 (TCF-64) cells were obtained and cultured as pre-
viously described [21] and were always cultured simultaneously in the
same conditions and at similar passages (4–8). Mouse embryonic fibro-
blast (MEF) cell lines (a generous gift from Dr R. A. DePinho) were
cultured as previously described [22]. Human umbilical vein endo-
thelial cells (HUVECs) and MDA-MB-231 were obtained from ATCC
(Manassas, VA) and were cultured following the instructions of the
company. U2OS and EH1 (a generous gift from Dr G. Peters) were
cultured as previously described [23]. All supplements were obtained
from Sigma (St Louis, MO) except for antibiotic and antimycotic
solutions, which were obtained from Gibco (Grand Island, NY). Akt
inhibitor III (Calbiochem, Rockland, MA) was dissolved in DMSO.
Cellular Lysate Preparation and Immunoblot Analysis
This has been performed as previously described [23]. Antibodies
directed against Akt, phospho-Akt (193H12), mammalian target of
rapamycin (mTOR, 7C10), and p.mTOR (Ser2448, D9C2) were
purchased from Cell Signaling Technology (Danvers, MA), VEGF-A
from Abcam (Cambridge, MA), p16 and CD31 from BD Biosciences
(San Jose, CA), glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
FL-335) from Santa Cruz Biotechnology (Santa Cruz, CA), and HIF-1α
(H1α67) from Millipore (Rockland, MA).
RNA Purification, Reverse Transcription–Polymerase Chain
Reaction, and Real-time Reverse Transcription–Polymerase
Chain Reaction
This has been performed as previously described [20].
The respective primers were:
β-actin: 5′-CCCAGCACAATGAAGATCAAGATCAT-3′ and
5′ ATCTGCTGGAAGGTGGACAGCGA-3′;
CDKN2A: 5′-CAACGCACCGAATAGTTACG-3′ and 5′-
CAGCTCCTCAGCCAGGTC-3′
VEGF-A: 5′-CCCACTGAGGAGTCCAACAT-3′ and 5′-
TTTCTTGCGCTTTCGTTTTT-3′.
siRNA Transfection
The transfection using CDKN2A-siRNA and control-siRNA was per-
formed as previously described [23]. The AKT-siRNA and its corre-
sponding control were obtained from Qiagen (Hilden, Germany), and
the transfections were carried out as recommended by the manufacturer.
Viral Infection
Lentivirus-based vector bearing CDKN2A-ORF (pIRES) as well as
its respective control (Addgene, Cambridge, MA) were used to pre-
pare the lentiviral supernatant from 293FT cells. Lentiviral super-
natants were collected 48 hours post-transfection, filtered, and used
for infection. Twenty-four hours later, media were replaced with com-
plete media (CpM) and cells were grown for 3 days.
Enzyme-linked Immunosorbent Assay
Supernatants from 24-hour fibroblast cell cultures were harvested
and ELISA was performed according to the manufacturer’s instructions
[R&D Systems (Minneapolis, MN) or Ray Bio (Brussels, Belgium) for
MMP-2]. The OD was used at 450 nm on a standard ELISA plate
reader. These experiments were performed in triplicates.
Chemotaxis and Invasion Assay
Cell migration and invasion were evaluated using 24-well BD Bio-
Coat Matrigel Invasion Chambers as per the manufacturer guideline
(BD Biosciences). In brief, 2 to 4 × 105 cells were added to the upper
wells separated by 0.8-μm pore-size polyethylene terephthalate (PET)
membrane with thin layer of matrigel basement membrane matrix (for
invasion) or without (for migration). The membranes were stained with
Diff-Quick stain (Fisher Scientific, Fair Lawn, NJ) after removing the
non-migrated cells from the top of the membrane with Q-tips. After
air-drying, the membranes were cut and mounted on slides with
oil, and cells that had migrated to the underside of the filter were
counted using light microscope (Zeiss Axio Observer) in five randomly
selected fields (original magnification, ×40). Each assay was performed
in triplicate.
Three-dimensional Matrigel Assay
Fibroblast cells (6 × 104) were seeded in the presence of CpM in
6-well plates coated with solidified BD Matrigel basement membrane
matrix. After 24 hours of incubation, cells were photographed.
Quantification of Protein and RNA Expression Levels
The expression levels of the immunoblotted proteins were measured
using a densitometer (BIO-RAD GS-800 Calibrated Densitometer), as
previously described [23].
HUVEC Endothelial Tube Formation Assay
The Chemicon In Vitro Angiogenesis Assay Kit was used. Wells in
96-well plates were coated with ice-cold EC matrix gel solution in the
EC matrix diluent buffer. After solidification of the matrix at 37°C,
5000 HUVECs were seeded onto the polymerized EC matrix in the
presence of 150 μl of RPMI per well. Media were immediately added
after plating HUVECs for a final 1:1 ratio of RPMI medium to
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conditioned media. After 4 hours of incubation, tubule branches
were photographed and their number was counted.
Conditioned Media
Cells were cultured in medium ± serum for 24 hours, and then
media were collected and briefly centrifuged. The resulting super-
natants were used either immediately or were frozen at −80°C
until needed.
Tumor Xenografts
Animal experiments were approved by the King Faisal Specialist
Hospital and Research Center Institutional Animal Care and Use
Committee and were conducted according to relevant national and
international guidelines. Animals were housed in the King Faisal Spe-
cialist Hospital and Research Center animal facility and they only
suffered needle injection pain and also certain degree of pain/distress
related to the growth/burden of the tumor. The euthanasia was per-
formed using CO2 chamber and cervical dislocation. Ten nude mice
were randomized into two groups, and breast cancer xenografts
were created by subcutaneous coimplantation of MDA-MB-231 cells
(2 × 106) with p16−/− or p16+/+ MEFs (106) into the right leg of
each mouse. After 49 days, the animals were scarified and tumors
were excised.
Evaluation of Microvessel Density in Tumor Xenografts
Paraffin-embedded sections from tumor xenografts were immuno-
stained using anti-CD31 antibody, and then the number of CD31-
positive vessels was counted in five different highest fields of microvessel
density (40× objective lens and 10× ocular lens).
Statistical Analysis
Statistical analysis was performed by Student’s t test and P values
of .05 and less were considered as statistically significant.
Results
p16 Represses Stromal Fibroblast Migration and Invasion
We have shown in a recent publication that p16 down-regulation
activates breast stromal fibroblasts [20]. Therefore, we sought to inves-
tigate whether p16 plays a role in stromal fibroblast migration and
invasion, two major features of active fibroblasts. To this end, we down-
regulated p16 in histologically normal TCF-64 cells using specific
Figure 1. p16 down-regulation enhances fibroblast migration and invasion. (A) Whole-cell lysates were prepared from TCF-64, CAF-64,
T64si, and T64C cells and were used for immunoblot analysis. The numbers below the bands indicate fold of induction after normalization
against GAPDH. (B, C) T64si and T64C cells (4 × 105) were cultured on the upper compartments of BioCoat Matrigel chambers in the
presence of SFM. After 24 hours of incubation, cells were stained with Diff-Quick stain and then counted. (B) Representative photographs
showing invasive andmigrated cells. Scale bars represent 20 μm. (C) Histograms depict average numbers of invasive andmigrated cells, and
error bars represent means ± SD. (D) Cells (6 × 104) were seeded with CpM in six-well plates coated with BDMatrigel basement membrane
matrix for 24 hours. Representative photographs show the morphology of the invading cells. Scale bars represent 30 μm.
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siRNA (T64si), and scrambled siRNA was used as control (T64C).
T64si and T64C cells had similar growth rate and were always treated
simultaneously. Cell lysates were prepared from these cells and from
TCF-64 and the corresponding CAF-64 cells, and the p16 protein
levels were assessed by immunoblot analysis. Figure 1A shows p16
down-regulation by CDKN2A-siRNA–expressing cells. It is note-
worthy that the expression of p14 was not affected in these cells [20].
Next, we assessed the migratory/invasiveness abilities of T64si and
T64C cells using BioCoat Matrigel chambers either coated (invasion)
or uncoated (migration). While CpM was added as chemoattractant
to the lower wells of the chambers, cells (4 × 105) were added to the
upper wells in the presence of serum-free media (SFM). After 24 hours
of incubation, cells were stained with Diff-Quick stain and then
counted. Figure 1, B and C , shows that the number of migrating and
invading p16-deficient cells was about two-fold higher than the number
of migrating (P = .00011) and invading (P = .0000035) control cells.
This suggests that p16 represses both the migratory and the invasiveness
abilities of breast stromal fibroblast cells.
We next investigated the role of p16 in the migration/invasion of
breast fibroblasts in in vitro three-dimensional (3D) matrigel assay.
Thereby, T64si and T64C cells (6 × 104) were embedded in the
BD Matrigel. While all cells formed spheroids in the matrigel, only
the p16-deficient fibroblasts showed invasive growth in a stellate pat-
tern with branching morphogenesis forming dendritic network of
extensions (Figure 1D). This shows that p16 down-regulation changes
the 3D shape and enhances the invasiveness of breast stromal fibroblasts
into matrigel.
p16 Negatively Regulates VEGF-A Expression in
Breast Stromal Fibroblasts
Because CAFs play a major role in angiogenesis and because the
increase in the migratory ability of stromal fibroblasts and their branch-
ing structure is thought to help the formation of new blood vessels [24],
we sought to investigate the possible role of p16 in the expression of the
main angiogenesis factor VEGF-A in stromal fibroblasts and the para-
crine effect on endothelial cells. To this end, the level of VEGF-A
was assessed in T64si and T64C cells. Figure 1A shows clear increase
(five-fold) in the level of VEGF-A in p16-deficient cells compared to
control cells. Similarly, the VEGF-A level is 16-fold higher in CAF-64
cells than in the corresponding TCF-64 cells (Figure 1A). In addition,
CAF-64 cells were transfected with lentivirus-based plasmids express-
ing CDKN2A (C64-ORF) or not (C64C), and then the level of the
VEGF-A protein was assessed. Figure 2A shows that the introduction
of the CDKN2A-ORF in CAF-64 cells increased the level of p16 and
concomitantly reduced the expression of VEGF-A. Similarly, the ex-
pression of p16 in the p16-defectrive osteosarcoma U2OS cells (EH1)
reduced the expression level of VEGF-A (Figure 2A). EH1 expresses
p16 under the control of an isopropyl β-D-1-thiogalactopyranoside
(IPTG)–inducible promoter, but in absence of IPTG there is a leaky ex-
pression, which does not exert any measurable effect on cellular growth
[25]. These results suggest that p16 represses the expression of VEGF-A.
To investigate the effect of p16 on the VEGF-A mRNA, total
RNA was purified from T64C and T64si cells, and real-time reverse
transcription–polymerase chain reaction (RT-PCR) using specific
primers was performed. Figure 2B shows that the mRNA level of
VEGF-A doubled in T64si cells compared to the control T64C (P =
.00082), indicating that the VEGF-A mRNA expression is mod-
ulated in a p16-dependent manner. To further show this, total
RNA was purified from C64-ORF and C64C cells and real-time
Figure 3. p16 represses VEGF-A secretion from breast stromal
fibroblasts. (A, B) Conditioned media from the indicated cells
were collected after 24 hours and the level of secreted VEGF-A
was determined by ELISA. Error bars represent means ± SD.
*P < .001.
Figure 2. p16 suppresses the expression of VEGF-A. (A) Cell lysates were prepared from the indicated cells and used for immunoblot
analysis using the indicated antibodies. (B, C) Total RNA was extracted from the indicated cells and the amount of the VEGF-A mRNA
was assessed by real-time RT-PCR. Error bars represent means ± SD. *P < .001.
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RT-PCR was performed. Figure 2C , upper panel, shows clear increase
in the level of CDKN2A in cells expressing the gene. The lower panel
shows that the introduction of the CDKN2A-ORF in CAF-64 cells
significantly reduced the expression of the VEGF-A mRNA (P =
.000742). This confirms the p16-dependent expression of the
VEGF-A gene.
p16 Suppresses the Secretion of VEGF-A from
Breast Stromal Fibroblasts
T64si and T64C cells were cultured in CpM for 24 hours, and
conditioned medium from each culture was collected and was used
to assess the level of secreted VEGF-A by ELISA. Figure 3A shows that
down-regulation of p16 significantly increased the secreted level of
VEGF-A (about three-fold). Furthermore, conditioned media from
C64-ORF and C64C cells were collected and the level of VEGF-A was
assessed by ELISA. Figure 3B shows that the increase in the level of the
p16 coding gene significantly reduced the secreted level of VEGF-A.
This indicates that p16 restrains the secretion of this angiogenesis-
promoting protein from breast stromal fibroblasts.
Breast Stromal Fibroblast p16 Suppresses Angiogenesis
SFM were conditioned with T64si and T64C cells for 24 hours
and were subsequently added separately to 96-well plates seeded with
0.5 × 105 HUVECs in matrigel and used for in vitro angiogenic assay.
SFM was also added as negative control. Figure 4A shows that after
4 hours of incubation the number of HUVECs that were differentiated
into closed cavity constructions was significantly higher in the
presence of serum-free conditioned media (SFCM) from T64si cells
compared to SFCM from T64C cells or SFM, with a P value of
.0000464. Similarly, the number of non-sprouting HUVECs was
4-fold and 4.5-fold lower in the presence of SFCM derived from
p16-deficient cells compared to p16-proficient cells (P = .0000357)
Figure 4. SFCM from p16-deficient human and mice fibroblasts activate HUVEC tube formation in a VEGF-A–dependent manner. SFCM
were collected after 24 hours of incubation from the indicated cells and were added independently on HUVECs plated on matrigel
(96-well plate), and the differentiation into capillary-like structures was assessed after 4 hours of incubation. (A) Representative
photographs of HUVEC cavities. Scale bars represent 30 μm. Stars show cavities and the circle indicates non-sprouting cells. (B) Histo-
grams show number of cavities and non-sprouting cells. (C) SFCM were collected from MEF cells. (D) SFCM from T64si cells were treated
with IgG1 or bevacizumab. The numbers between brackets indicate bevacizumab concentrations in μM. (E) Breast cancer xenografts were
created by co-injecting MDA-MB-231 cells with p16−/− or p16+/+ MEFs subcutaneously into nude mice. Immunohistochemistry was
carried out on tumors containing MEFs either p16−/− or p16+/+ using anti–CD-31 antibody. Scale bars represent 30 μm. Histogram
shows average number of microvessels observed in five different fields from two different tumors. Error bars represent means ± SD.
*P < .001.
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and SFM, respectively (Figure 4B). Similar results were obtained with
MEF-p16−/− SFCM compared to MEF-p16+/+ SFCM (Figure 4C).
These results illustrate the role of the stromal fibroblast p16 protein in
inhibiting endothelial cell differentiation into capillary-like structures
through paracrine effect.
To ascertain the role of stromal fibroblast–secreted VEGF-A in the
differentiation of HUVECs, SFCM from T64si cells were treated
with IgG1 (control) or increasing concentrations of the anti–VEGF-A
inhibitory antibody bevacizumab. Figure 4D shows that the number
of HUVECs that were differentiated into closed cavity constructions
decreased in a dose-dependent manner. In response to 1 μMbevacizumab,
only 25% of the cavities were formed compared to the control cells
treated with IgG1 (Figure 4D). This shows that p16-deficient stromal
fibroblast-dependent activation of HUVEC differentiation is indeed
VEGF-A related.
To investigate the effect of p16 deficiency in fibroblasts on angio-
genesis in vivo, 10 nude mice were randomized into two groups and
breast cancer xenografts were created subcutaneously by coimplanta-
tion of MDA-MB-231 cells (2 × 106) with p16−/− or p16+/+ MEFs
(106) into the right leg of each mouse. After the formation of the
tumors, we examined the paracrine effect of p16 on vascular forma-
tion in tumor xenografts by immunohistochemistry using anti-CD31
antibody, an endothelial cell marker. Figure 4E shows higher density
of CD31-positive vessels in tumors containing MEF-p16−/− cells
compared to xenograft tumors admixed with normal MEFs. Interest-
ingly, the assessment of the averaged microvascular density in both
tumor xenografts showed two-fold greater level in tumors containing
MEF-p16−/− when compared with tumors containing normal counter-
part MEF cells (Figure 4E). This further shows the antiangiogenesis
role of stromal fibroblast p16.
p16 Inhibits the Akt/mTOR Pathway
To explore the molecular mechanisms that underlay p16-dependent
modulation in stromal fibroblast migration/invasion and their pro-
angiogenic effects, we studied the effect of CDKN2A down-regulation
on the phosphorylation/activation of Akt, a known proinvasive and
proangiogenesis protein kinase [9,26]. Figure 5A shows that while
the level of Akt was not affected with p16 knockdown, the level of
the active form of the protein was upregulated in p16-deficient cells
compared to their control cells. To further elucidate the role of p16
in Akt inhibition, we checked the status of Akt in CAF-64 cells expres-
sing the CDKN2A gene and their respective control cells. Figure 5B
shows that p16 expression in CAF-64 reduced the level of the active
form of the Akt protein kinase. Similarly, while p16-defective U2OS
cells express high level of the phosphorylated Akt protein, the isogenic
p16-proficient EH1 cells express only a low amount of the active Akt
(Figure 5B). This indicates that p16 inhibits Akt, which could explain
the increase in the migration/invasion ability of p16-deficient breast
stromal fibroblasts.
Active Akt induces angiogenesis through the activation of the
mTOR and HIF-1α genes [27]. To test this, we assessed the levels
of these proteins in p16-deficient cells compared to their control
counterparts. Figure 5A shows that the activation of Akt in p16-
deficient cells was accompanied by activation of the mTOR protein
and the up-regulation of its major target HIF-1α, which is a pos-
itive regulator of VEGF-A and angiogenesis [28]. However, p16
expression in p16-deficient CAF-64 and U2OS cells reduced the
level of the active mTOR and its downstream effector HIF-1α
(Figure 5B). This confirms the role of p16 deficiency in the activation
of the Akt pathway.
p16 Represses Stromal Fibroblasts Migration and Their
Proangiogenic Effect through Inhibiting the Akt Pathway
To confirm the role of Akt in mediating p16 deficiency–related en-
hancement of stromal fibroblast migration/invasion and angiogenesis,
we inhibited this kinase in T64si using both Akt inhibitor III at 10 μM
for 18 hours and a specific Akt-siRNA. At this concentration, Akt in-
hibitor III had no effect on cell proliferation or cytotoxicity. Figure 6A
shows the inhibitory effect of the Akt inhibitor and Akt-siRNA on the
expression level of Akt and phopho-Akt. As expected, while inhibitor
III affected the level of the active form of the protein, Akt-siRNA re-
duced the level of both total and phospho-Akt (Figure 6A). Next, we
investigated the effect of Akt inhibition on invasion/migration as de-
scribed in Figure 1B. Interestingly, Akt inhibition strongly reduced
the migratory and invasiveness abilities of p16-deficient stromal fibro-
blasts (Figure 6, B and C ). Similarly, Akt inhibitor III suppressed the
invasive growth of these cells into matrigel compared to their control
counterpart cells (Figure 6D). This indicates that the p16-related in-
crease in the migration/invasion abilities of breast stromal fibroblasts
is Akt-dependent.
To assess the effect on angiogenesis, SFM conditioned with T64si
cells pretreated with DMSO or Akt inhibitor III were collected and
were added to HUVECs as described in Figure 4A. Figure 6E shows
that after 4 hours of incubation in the presence of SFCM from con-
trol cells, HUVECs were differentiated into closed cavities. However,
no differentiation was observed in the presence of SFCM from Akt
inhibitor–treated cells. Similar effects were obtained when Akt was
inhibited by specific siRNA (data not shown), showing that p16 in-
hibits the proangiogenic effect of stromal fibroblasts by suppressing
the Akt pathway.
Discussion
When active, CAFs become more invasive and prepare the milieu for
cancer spread through activating neovascularization in a paracrine
manner [4,29]. Both cancer epithelial cells and stromal fibroblasts are
interdependent for their migratory behavior through cross-signaling;
however, it still unclear which cell population starts invading the
other one. To do so, active stromal fibroblasts need to traverse the
extracellular matrix and the basement membrane. We have shown
here that p16 down-regulation enhances the migratory and the in-
vasiveness abilities of mammary stromal fibroblasts. Furthermore,
p16 down-regulation changed also the 3D structure of breast
Figure 5. p16 represses the Akt/mTOR/HIF-1α pathway. (A, B)Whole-
cell lysates were prepared from the indicated cells and were used
for immunoblot analysis using the indicated antibodies.
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fibroblasts by triggering the formation of branching structures with
dendritic network of extensions and also increased their invasiveness
into matrigel, which is an in vitro mimic of the basement membrane
(Figure 1). This reveals that p16 repression may be critical in in-
creasing the ability of stromal fibroblasts in moving and invading
the epithelial compartment. During mammary carcinogenesis, this
could constitute an important step toward the transition from ductal
carcinoma in situ (DCIS) to invasive ductal carcinoma, because the
basement membrane is largely intact in ductal carcinoma in situ.
Besides, these branching structures of activated fibroblasts could also
increase the efficiency of stromal fibroblasts in recruiting endothelial
progenitor cells and the formation of blood vessels. Indeed, we have
also shown that p16-deficient fibroblasts express and secrete higher
levels of the proangiogenesis factor VEGF-A and enhance endothe-
lial cell differentiation into capillary-like structures and angiogenesis
in vivo in breast tumor xenografts.
In a previous study, Li et al. have shown that adenoviral-mediated
p16 expression downregulated the VEGF-A gene expression in breast
cancer cells and suppressed breast cancer cell–induced angiogenesis
[30]. Similarly, restoration of p16 reduced the VEGF-A expression
level and inhibited angiogenesis in human gliomas [31]. In the pres-
ent study, we have shown that p16 represses the VEGF-A expression
at both mRNA and protein levels in breast fibroblasts. Indeed, while
p16 down-regulation increased the VEGF-A mRNA and protein
levels, p16 expression decreased the level of the VEGF-A mRNA,
suggesting that p16 controls the expression of VEGF-A at the tran-
scriptional or post-transcriptional level.
These results raised an important question regarding how p16
controls these two important cancer-promoting processes: fibroblast
migratory ability and the synthesis/secretion of the proangiogenic
factor VEGF-A. Interestingly, both of these processes are under
the control of the important protein kinase Akt [32]. We have shown
that p16 negatively controls Akt, and the inhibition of this kinase
suppressed the migration/invasion abilities of p16-deficient stromal
fibroblasts and also their paracrine proangiogenesis effect.
To elucidate the molecular pathway underlying the p16-dependent
repression of the VEGF-A expression, we tested the effect of p16
down-regulation on HIF-1α, the major transcriptional activator of
VEGF-A, which is also under the control of the Akt/mTOR pathway
[33]. Interestingly, we have found the HIF-1α gene upregulated in
p16-deficient cells. This suggests that p16 negatively regulates
VEGF-A through inhibition of HIF-1α. This effect seems to take
place through the inhibition of the Akt/mTOR pathway. Indeed,
p16 down-regulation activated mTOR (Figure 5).
Figure 6. p16 represses stromal fibroblasts migration/invasion and their proangiogenic effect through Akt inhibition. (A) T64si cells were
treated with Akt inhibitor III (10 μM) and DMSO (−) for 18 hours (upper panel) or cells were treated with control-siRNA and Akt-siRNA
(lower panel), and whole-cell lysates were prepared and used for immunoblot analysis using the indicated antibodies. (B, D, E) T64si
cells were treated either with Akt inhibitor III (10 μM) or DMSO. (B, D) The migration and invasion abilities were assessed using matrigel
chambers as in Figure 1C. Error bars represent means ± SD. *P < .001 (B), or BD matrigel basement membrane matrix as in Figure 1D
(D). (C) T64si cells were treated either with control-siRNA or Akt-siRNA, and the migration/invasion abilities of these cells were assessed
as in Figure 1C. Representative photographs of migrating and invading cells are shown. Error bars represent means ± SD. (E) SFCM
were collected and were added independently on HUVECs plated on matrigel (96-well plate), and the differentiation into capillary-like
structures was assessed after 4 hours of incubation. Representative photographs of HUVEC cavities are shown. Scale bars represent
30 μm.
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How does p16 regulate the activity/expression of these genes? In
fact, several lines of evidence indicate that p16 is not a mere CDK
inhibitor. p16 overexpression has also been found in some benign
tumors and in some cancer types, such as cervical cancer, breast
cancer, and head and neck cancer [34,35]. Therefore, it is possible
that this p16 function is mediated through interaction with other pro-
teins. Indeed, it has been shown that p16 interacts with several proteins
involved directly or indirectly in the control of gene expression such as
HSP90, EF-2, hnRNP C1, and others [36]. Furthermore, it has been
recently shown that p16 interacts with GRAM-19 to regulate E2F1-
responsive gene expression [37]. Moreover, p16 down-regulation by
specific siRNA modulated the expression of more than 2000 genes im-
plicated in different cellular processes [38]. Additionally, Chien et al.
have shown the implication of p16 in controlling the expression of sev-
eral miRNA in cancer cells [39]. This indicates that p16 may regulate
gene expression at different levels through protein-protein interactions
and modulating the expression of various key transcription factors.
The fact that p16 represses both migration/invasion of breast
stromal fibroblasts and their proangiogenic effect indicates that the
loss of this tumor suppressor gene plays a major role in the activation
of these cells and consequently in tumor growth and spread. We have
recently shown that p16 is downregulated in 83% breast CAFs com-
pared to their adjacent counterpart primary cells and also in breast
cancer tissues in situ. Furthermore, specific p16 down-regulation
enhanced the procarcinogenic effects of breast stromal fibroblasts
both in vitro and in tumor xenografts [20]. Additionally, p16 pro-
moter hypermethylation and transcriptional silencing have been
detected in histologically normal mammary tissue of cancer-free
women. This led to COX-2 overexpression and promotion of pre-
malignant program, including increased angiogenic activity [40,41].
This shows that loss of p16 function promotes tumorigenesis and
angiogenesis not only from cancer cells [30,31] but also from the
abundant activated stromal fibroblasts in a paracrine fashion. There-
fore, pharmacologic restoration of p16 level in breast stroma could
be of great therapeutic value.
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